1982EndocrinologyRequires access

Equine Cushing's Disease: Plasma Immunoreactive Proopiolipomelanocortin Peptide and Cortisol Levels Basally and in Response to Diagnostic Tests*

David N. Orth, Myron A. Holscher, Margaret G. Wilson, Wendell E. Nicholson, Raymond E. Plue, Charles D. Mount

Open publisher page 146 citations

Abstract

Equine Cushing's disease is almost invariably caused by ACTH hypersecretion by adenomas of pars intermedia (PI), rather than pars distalis (PD), as in man. Therefore, PI proopiolipomelanocortin (proOLMC) peptides, such as αMSH, βMSH, corticotropin-like intermediate lobe peptide (CLIP), and β-endorphin (βEND), are also secreted. In two horses with Cushing's disease, basal plasma immunoreactive ACTH was elevated about the same as in human Cushing's disease, but αMSH, βMSH, CLIP, and βEND were disproportionately increased. Neither they nor the modestly elevated plasma cortisol demonstrated a diurnal rhythm. In the mare with more severe disease, neither low nor high dose dexamethasone suppressed hormone levels; in the less affected mare, high dose dexamethasone suppressed peptide levels only modestly, and cortisol never fell below normal. Both mares had glucose intolerance. Insulin (0.8 U/kg) did not lower blood glucose in the mare with severe Cushing's disease and diabetes mellitus; in the other, there was little response of peptides or cortisol, although blood glucose fell to 34 mg/dl. The adrenal cortices of both animals responded to exogenous ACTH. The less affected mare was studied further. Vasopressin was followed by only a modest increase in hormone levels at 60 min or later, which may have represented a spontaneous fluctuation in secretion. Dopamine infusion caused a prompt fall in hormone levels, followed by a rebound after it was stopped. Bromocriptine and pergolide, dopaminergic agonists, caused prompt and sustained decreases in hormone levels, but not to less than normal. Combined pergolide and dexamethasone lowered hormone levels still further, supporting the concept that dexamethasone had suppressed residual PD secretion. The results suggest that proOLMC peptide secretion by a PI adenoma causing equine Cushing's disease is under similar control as normal PI in other species. Glucocorticoids, which suppress PD but not PI secretion, and vasopressin and hypoglycemia, which stimulate PD but not PI secretion, had little or no effect on PI tumor proOLMC secretion; in contrast, dopamine, which inhibits PI but not PD proOLMC peptide secretion, also inhibited PI tumor secretion and thereby provides a potential rationale for treating Cushing's disease in horses.

About this research paper

What this paper is about

Equine Cushing's disease is almost invariably caused by ACTH hypersecretion by adenomas of pars intermedia (PI), rather than pars distalis (PD), as in man. Therefore, PI proopiolipomelanocortin (proOLMC) peptides, such as αMSH, βMSH, corticotropin-like intermediate lobe peptide (CLIP), and β-endorphin (βEND), are also secreted. In two horses with Cushing's disease, basal plasma immunoreactive ACTH was elevated about the same as in human Cushing's disease, but αMSH, βMSH, CLIP, and βEND were disproportionately increased. Neither they nor the modestly elevated plasma cortisol demonstrated a diurnal rhythm. In the mare with more severe disease, neither low nor high dose dexamethasone suppressed hormone levels; in the less affected mare, high dose dexamethasone suppressed peptide levels only modestly, and cortisol never fell below normal. Both mares had glucose intolerance. Insulin (0.8 U/kg) did not lower blood glucose in the mare with severe Cushing's disease and diabetes mellitus; in the other, there was little response of peptides or cortisol, although blood glucose fell to 34 mg/dl. The adrenal cortices of both animals responded to exogenous ACTH. The less affected mare was studied further. Vasopressin was followed by only a modest increase in hormone levels at 60 min or later, which may have represented a spontaneous fluctuation in secretion. Dopamine infusion caused a prompt fall in hormone levels, followed by a rebound after it was stopped. Bromocriptine and pergolide, dopaminergic agonists, caused prompt and sustained decreases in hormone levels, but not to less than normal. Combined pergolide and dexamethasone lowered hormone levels still further, supporting the concept that dexamethasone had suppressed residual PD secretion. The results suggest that proOLMC peptide secretion by a PI adenoma causing equine Cushing's disease is under similar control as normal PI in other species. Glucocorticoids, which suppress PD but not PI secretion, and vasopressin and hypoglycemia, which stimulate PD but not PI secretion, had little or no effect on PI tumor proOLMC secretion; in contrast, dopamine, which inhibits PI but not PD proOLMC peptide secretion, also inhibited PI tumor secretion and thereby provides a potential rationale for treating Cushing's disease in horses.

Why it matters

OpenAlex reports 146 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Equine Cushing's disease is almost invariably caused by ACTH hypersecretion by adenomas of pars intermedia (PI), rather than pars distalis (PD), as in man. Therefore, PI proopiolipomelanocortin (proOLMC) peptides, such as αMSH, βMSH, corticotropin-like intermediate lobe peptide (CLIP), and β-endorphin (βEND), are also secreted. In two horses with Cushing's disease, basal plasma immunoreactive ACTH was elevated about the same as in human Cushing's disease, but αMSH, βMSH, CLIP, and βEND were disproportionately increased. Neither they nor the modestly elevated plasma cortisol demonstrated a diurnal rhythm. In the mare with more severe disease, neither low nor high dose dexamethasone suppressed hormone levels; in the less affected mare, high dose dexamethasone suppressed peptide levels only modestly, and cortisol never fell below normal. Both mares had glucose intolerance. Insulin (0.8 U/kg) did not lower blood glucose in the mare with severe Cushing's disease and diabetes mellitus; in the other, there was little response of peptides or cortisol, although blood glucose fell to 34 mg/dl. The adrenal cortices of both animals responded to exogenous ACTH. The less affected mare was studied further. Vasopressin was followed by only a modest increase in hormone levels at 60 min or later, which may have represented a spontaneous fluctuation in secretion. Dopamine infusion caused a prompt fall in hormone levels, followed by a rebound after it was stopped. Bromocriptine and pergolide, dopaminergic agonists, caused prompt and sustained decreases in hormone levels, but not to less than normal. Combined pergolide and dexamethasone lowered hormone levels still further, supporting the concept that dexamethasone had suppressed residual PD secretion. The results suggest that proOLMC peptide secretion by a PI adenoma causing equine Cushing's disease is under similar control as normal PI in other species. Glucocorticoids, which suppress PD but not PI secretion, and vasopressin and hypoglycemia, which stimulate PD but not PI secretion, had little or no effect on PI tumor proOLMC secretion; in contrast, dopamine, which inhibits PI but not PD proOLMC peptide secretion, also inhibited PI tumor secretion and thereby provides a potential rationale for treating Cushing's disease in horses.

Key concepts: Internal medicine, Endocrinology, Medicine, Dexamethasone, Cushing's disease, Basal (medicine), Pergolide, Hormone

Related papers

Back to paper searchBrowse research topicsOriginal source
Equine Cushing's Disease: Plasma Immunoreactive Proopiolipomelanocortin Peptide and Cortisol Levels Basally and in Response to Diagnostic Tests* — Research Paper | ScholarLens